In summary, although many complicated questions have not been answered, our study was the first to identify the mTOR/HIF1α/ENO1 pathway in thyroid carcinoma progression and ENO1 as a regulator of CST1, thereby paving the way for early diagnosis and efficient therapy of thyroid carcinoma. Here, ENO1 is linked to thyroid gland carcinoma.